Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Loading...
Loading...

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). 

  • Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Holdings AG RHHBY, as part of the companies' long-standing collaboration on antibodies targeting CD20.
  • Biogen will have joint decision-making rights related to the development and commercialization of mosunetuzumab, and Genentech will continue to lead the strategy and implementation of the program.
  • In June 2020, mosunetuzumab was granted Breakthrough Therapy Designation (BTD) by the FDA for adult patients with relapsed/refractory (R/R) FL who have received at least two prior systemic therapies.
  • In addition, mosunetuzumab recently began a Phase 1b trial in patients with systemic lupus erythematosus.
  • Biogen will share in the operating profits and losses of mosunetuzumab in the U.S. in the low to mid 30% range and is eligible to receive low single-digit royalties on sales outside the U.S.
  • Price Action: BIIB shares are up 1.14% at $228.58 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefsDiffuse Large B-Cell LymphomaFollicular LymphomaNon Hodgkin Lymphoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...